Moderna announces Phase 3 trial results for mRNA-1283, its next-gen COVID-19 vaccine. A higher immune response was observed ...
Moderna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab in ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
The US Food and Drug Administration (FDA) approved the latest versions of COVID-19 ... updated vaccines will be critical to protecting the population this season,” Moderna CEO Stéphane Bancel ...
On December 14, 2020, Sandra Lindsay, a nurse at New York’s Long Island Jewish Medical Center, became the first person to receive a non-trial dose of the COVID-19 vaccine in the United States ...
(Jon Cherry/Getty Images) A Defense Department Inspector General review of the military’s COVID vaccine exemption process found that while the services largely followed policy when considering ...
The SII has been the largest vaccine manufacturer globally for several years but saw its profile rise substantially after manufacturing millions of cheap Covid vaccine shots for export at the height ...
A nurse shows the Moderna COVID-19 vaccine at Northwell Health's Long Island Jewish Valley Stream hospital in New York, Dec. 21, 2020. Eduardo Munoz/Reuters Regeneron is a drug cocktail consisting ...
Acetaminophen or ibuprofen may dull the effectiveness of the vaccine. COVID-19 vaccines from Pfizer-BioNTech and Moderna are being offered to an increasing number of people. Vaccine recipients ...
The Moderna (Nasdaq: MRNA) CEO’s compensation last year included a base salary of about $1.56 million, which was actually an increase ... vaccine-maker. The company saw a drop in interest in ...
Moderna is working to cut costs as its Covid-19 vaccine sales fade after years of beefed-up research and development spending during the pandemic, but still wants to come out of the spending cuts ...
Despite Moderna’s efforts to prove its mRNA thesis beyond COVID-19 in 2023, the post-pandemic hangover took a toll on the company. In turn, much of the company’s top brass—including CEO ...